Athaya Vorasittha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Athaya Vorasittha has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anapat Sanpavat
Department of Pathology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok Thailand
1 shared publication Bunthoon Nonthasoot
Department of Surgery, Faculty of Medicine Chulalongkorn University & King Chulalongkorn Memorial Hospital Bangkok Thailand
1 shared publication- Chandramouli Radhakrishnan
Certara Radnor Pennsylvania USA
1 shared publication - Piyawat Komolmit
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
1 shared publication - Prawat Chantharit
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University Bangkok Thailand
1 shared publication - Sirinporn Suksawatamnuay
Excellence Center in Liver Diseases King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9) , e70339
Precision Dosing of Tacrolimus in Liver Transplantation: Integrating Donor‐Recipient CYP3A5 Pharmacogenomics and Drug Interactions
Tacrolimus dosing in liver transplantation is complicated by a narrow therapeutic index and high CYP3A5 genetic variability. While saturable Michaelis–Menten kinetics can explain nonlinearities, identifying saturable parameters from routine clinical data remains challenging. This study aimed to determine the optimal structural model and develop a precision dosing algorithm. A population pharmacokinetic analysis was conducted in 114 patients, yielding 1989 observations. CYP3A5 genotypes were determined for both recipients and donors. Using Phoenix NLME, we rigorously compared linear versus Michaelis–Menten elimination structures. Stepwise covariate modeling was conducted to quantify the impact of genetic, physiological, and pharmacological factors, followed by Monte Carlo simulations to optimize dosing. A conventional two‐compartment model adequately described the data without requiring a Michaelis–Menten structure. The combined CYP3A5 genotype exhibited a distinct stepwise reduction in apparent clearance from the homozygous expressor to the non‐expressor group. Fluconazole emerged as a major inhibitor, reducing clearance by 33%, whereas prednisolone showed modest induction. Hemoglobin displayed a significant inverse relationship with clearance. Crucially, incorporating the daily dose as a covariate on clearance effectively captured the apparent nonlinear disposition. Simulations confirmed that fluconazole‐treated patients require substantially lower doses (1.5–3.0 mg every 12 h) compared with fluconazole‐free patients (2.5–7.0 mg every 12 h). A dose‐dependent two‐compartment model offers a basis for model‐informed dose selection, addressing reported nonlinearities through physiological covariates. We provide a model‐informed dosing algorithm that accounts for combined recipient/donor genetics and drug interactions, which may improve target attainment in liver transplant populations.
- 3 September 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9) , e70339
Open AccessPrecision Dosing of Tacrolimus in Liver Transplantation: Integrating Donor‐Recipient CYP3A5 Pharmacogenomics and Drug Interactions
Tacrolimus dosing in liver transplantation is complicated by a narrow therapeutic index and high CYP3A5 genetic variability. While saturable Michaelis–Menten kinetics can explain nonlinearities, identifying saturable parameters from routine clinical data remains challenging. This study aimed to determine the optimal structural model and develop a precision dosing algorithm. A population pharmacokinetic analysis was conducted in 114 patients, yielding 1989 observations. CYP3A5 genotypes were determined for both recipients and donors. Using Phoenix NLME, we rigorously compared linear versus Michaelis–Menten elimination structures. Stepwise covariate modeling was conducted to quantify the impact of genetic, physiological, and pharmacological factors, followed by Monte Carlo simulations to optimize dosing. A conventional two‐compartment model adequately described the data without requiring a Michaelis–Menten structure. The combined CYP3A5 genotype exhibited a distinct stepwise reduction in apparent clearance from the homozygous expressor to the non‐expressor group. Fluconazole emerged as a major inhibitor, reducing clearance by 33%, whereas prednisolone showed modest induction. Hemoglobin displayed a significant inverse relationship with clearance. Crucially, incorporating the daily dose as a covariate on clearance effectively captured the apparent nonlinear disposition. Simulations confirmed that fluconazole‐treated patients require substantially lower doses (1.5–3.0 mg every 12 h) compared with fluconazole‐free patients (2.5–7.0 mg every 12 h). A dose‐dependent two‐compartment model offers a basis for model‐informed dose selection, addressing reported nonlinearities through physiological covariates. We provide a model‐informed dosing algorithm that accounts for combined recipient/donor genetics and drug interactions, which may improve target attainment in liver transplant populations.